Beckman Coulter introduces Dxl 9000 next-generation immunoassay analyser

Leading clinical diagnostics firm Beckman Coulter has unveiled the DxI 9000 Access Immunoassay Analyser, the most productive immunoassay analyser per footprint, capable of running up to 215 tests per hour per square metre.

The DxI 9000 analyser innovations address today’s speed, reliability, reproducibility, quality, and menu expansion demands. The platform has been independently verified to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level, the highest level of EFLM performance evaluation. At the same time, the novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays, ensuring the system is able to meet the healthcare needs of tomorrow.

According to Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics: “The DxI 9000 Access Immunoassay Analyser sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow’s analytical needs. Those in the laboratory will treasure ZeroDaily Maintenance to save them time, PrecisionVision Technology to safeguard against flawed data reports, and IntelliServe to maximise system uptime. At the same time, clinical researchers are excited about the DxI 9000’s capability to keep pace with increasingly sensitive testing requirements as healthcare providers and pharmaceutical companies take aim at ever more challenging diseases. The DxI 9000 is a comprehensive healthcare innovation.” 

An early evaluator of the DxI 9000, Dr Pamela Christudoss, Professor and Head, Department of Clinical Biochemistry, Christian Medical College Vellore, India noted: “Like clinical laboratories worldwide, we are running more tests than any time in our history. The innovations packed into the DxI 9000 will enable labs across the globe to improve their throughput rates and turnaround times with world-class precision.”

ZeroDaily Maintenance highlights the embedded innovations that drive the DxI 9000’s uptime performance. Beta users attest to ZeroDaily Maintenance reducing annual maintenance routines by up to 96%.  

Building on Beckman Coulter’s strengths in workflow and automation, PrecisionVision Technology is able to inspect, identify and prevent erroneous reporting in real time. PrecisionVision automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check reduces the risk of reporting flawed data and increases system reliability and reproducibility.

Beckman Coulter’s newly designed remote service and diagnostics solution, DxS IntelliServe, connects with DxI 9000 analysers to monitor data and error trends, enabling timely, proactive system service when needed. In addition, the DxS IntelliServe solution identifies service experts to resolve issues with real-time monitoring, remote operation, and troubleshooting to maximize laboratory uptime and performance. Equally impactful, IntelliServe's remote update capabilities and proactive scheduling ensures systems are always running on the most up-to-date software, reducing unplanned workflow interruptions or downtime.

The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.


Latest Issues